Infectious complications in non-myeloablative conditioning and allogeneic peripheral blood stem cell transplantation for patients with multiple myeloma.

被引：0
|
作者：
Lee, CK
Dignani, C
Barlogie, B
Guido, T
Morris, CL
Badros, AZ
Cottler-Fox, MH
van Rhee, F
Zanagari, M
Fassas, A
Anaissie, EJ
机构：
[1] Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Little Rock, AR 72205 USA
[2] Hosp Clin Sao Paulo, Sao Paulo, Brazil
[3] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA
[4] Loma Linda Univ, Med Ctr, Loma Linda, CA 92350 USA
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2471
引用
收藏
页码：627A / 627A
页数：1
相关论文
共 50 条
  • [1] High rates of infectious complications associated with HLA-mismatched or unrelated donor allogeneic peripheral blood stem cell transplantation after non-myeloablative conditioning for patients with multiple myeloma.
    Lee, CK
    Barlogie, B
    Morris, CL
    Badros, AZ
    van Rhee, F
    Cottler-Fox, MH
    Anaissie, EJ
    Zangari, M
    Fassas, A
    Thertulien, R
    Muwalla, F
    Tricot, G
    BLOOD, 2002, 100 (11) : 859A - 859A
  • [2] Treatment of multiple myeloma with an allogeneic peripheral blood stem cell transplantation using a non-myeloablative conditioning regimen
    Kmonicek, M
    Zak, P
    Jebavy, L
    Maisnar, V
    Maly, J
    BONE MARROW TRANSPLANTATION, 2003, 31 : S86 - S86
  • [3] NON-MYELOABLATIVE CONDITIONING AND ALLOGENEIC TRANSPLANTATION FOR MULTIPLE MYELOMA
    Osman, K.
    Elliott, B.
    Mandeli, J.
    Scigliano, E.
    Ross-Dodds, V.
    Isola, L.
    Grosskreutz, C.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (02) : 71 - 71
  • [4] Non-myeloablative conditioning and allogeneic transplantation for multiple myeloma
    Osman, Keren
    Elliott, Brian
    Mandeli, John
    Scigliano, Eileen
    Malone, Adriana
    Isola, Luis
    Grosskreutz, Celia
    AMERICAN JOURNAL OF HEMATOLOGY, 2010, 85 (04) : 249 - 254
  • [5] Non-myeloablative allogeneic transplantation in patients with relapsed or refractory multiple myeloma.
    Gerull, S
    Hegenbart, U
    Goerner, M
    Benner, A
    Moehler, T
    Goldschmidt, H
    Ho, AD
    BLOOD, 2004, 104 (11) : 755A - 755A
  • [6] Non-myeloablative stem cell transplantation is safe and effective for patients with multiple myeloma.
    Cogle, CR
    Moreb, JS
    Leather, HL
    Wiggins, LE
    Finiewicz, KA
    Khan, SA
    Reddy, VS
    Wingard, JR
    BLOOD, 2002, 100 (11) : 461B - 461B
  • [7] A comparison of outcome for patients undergoing non-myeloablative stem cell transplantation compared to conventional conditioning for multiple myeloma.
    Hunter, HM
    Peggs, K
    Powles, R
    Apperley, J
    Mahendra, P
    Cavenagh, J
    Littlewood, T
    Potter, M
    Hunter, A
    Pagliuca, A
    Williams, C
    Cook, G
    Towlson, K
    Marks, D
    Russell, NH
    BLOOD, 2003, 102 (11) : 732A - 732A
  • [8] Non-myeloablative allogeneic transplantation in patients with high-risk multiple myeloma.
    Gerull, S
    Probst, S
    Ho, AD
    Goldschmidt, H
    Goerner, M
    Schaefer, H
    BLOOD, 2003, 102 (11) : 475B - 475B
  • [9] High-dose melphalan and autologous stem cell transplantation followed by non-myeloablative conditioning regime and allogeneic stem cell transplantation as consolidation therapy in multiple Myeloma.
    Schneider, P
    Fenk, R
    Bernhardt, A
    Rohr, U
    Till, E
    Wehmeier, A
    Haas, R
    Kobbe, G
    BLOOD, 2001, 98 (11) : 351B - 351B
  • [10] Low incidence of infectious complications after non-myeloablative compared with myeloablative allogeneic stem cell transplantation
    Meijer, E
    Dekker, A
    Lokhorst, H
    Petersen, E
    Nieuwenhuis, K
    BONE MARROW TRANSPLANTATION, 2005, 35 : S198 - S198
12345